» Articles » PMID: 36012300

Membrane Internalization Mechanisms and Design Strategies of Arginine-Rich Cell-Penetrating Peptides

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Aug 26
PMID 36012300
Authors
Affiliations
Soon will be listed here.
Abstract

Cell-penetrating peptides (CPPs) have been discovered to deliver chemical drugs, nucleic acids, and macromolecules to permeate cell membranes, creating a novel route for exogenous substances to enter cells. Up until now, various sequence structures and fundamental action mechanisms of CPPs have been established. Among them, arginine-rich peptides with unique cell penetration properties have attracted substantial scientific attention. Due to the positively charged essential amino acids of the arginine-rich peptides, they can interact with negatively charged drug molecules and cell membranes through non-covalent interaction, including electrostatic interactions. Significantly, the sequence design and the penetrating mechanisms are critical. In this brief synopsis, we summarize the transmembrane processes and mechanisms of arginine-rich peptides; and outline the relationship between the function of arginine-rich peptides and the number of arginine residues, arginine optical isomers, primary sequence, secondary and ternary structures, etc. Taking advantage of the penetration ability, biomedical applications of arginine-rich peptides have been refreshed, including drug/RNA delivery systems, biosensors, and blood-brain barrier (BBB) penetration. Understanding the membrane internalization mechanisms and design strategies of CPPs will expand their potential applications in clinical trials.

Citing Articles

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.

Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W Signal Transduct Target Ther. 2025; 10(1):74.

PMID: 40038239 PMC: 11880366. DOI: 10.1038/s41392-024-02107-5.


A BAG-1-inhibitory peptide, GO-Pep, suppresses c-Raf activity in cancer.

Tatli O, Cebi E, Turk M, Dingiloglu B, Sezan A, Basturk E Commun Biol. 2025; 8(1):336.

PMID: 40021821 PMC: 11871328. DOI: 10.1038/s42003-024-07419-4.


Applications of cell penetrating peptide-based drug delivery system in immunotherapy.

Du J, Zhang R, Jiang S, Xiao S, Liu Y, Niu Y Front Immunol. 2025; 16:1540192.

PMID: 39911386 PMC: 11794548. DOI: 10.3389/fimmu.2025.1540192.


Emerging Nanoparticle-Based Diagnostics and Therapeutics for Cancer: Innovations and Challenges.

Puttasiddaiah R, Basavegowda N, Lakshmanagowda N, Raghavendra V, Sagar N, Sridhar K Pharmaceutics. 2025; 17(1).

PMID: 39861718 PMC: 11768644. DOI: 10.3390/pharmaceutics17010070.


A bird's-eye view of the biological mechanism and machine learning prediction approaches for cell-penetrating peptides.

Ramasundaram M, Sohn H, Madhavan T Front Artif Intell. 2025; 7():1497307.

PMID: 39839972 PMC: 11747587. DOI: 10.3389/frai.2024.1497307.


References
1.
Fuselier T, Wimley W . Spontaneous Membrane Translocating Peptides: The Role of Leucine-Arginine Consensus Motifs. Biophys J. 2017; 113(4):835-846. PMC: 5567601. DOI: 10.1016/j.bpj.2017.06.070. View

2.
Zhang P, Lock L, Cheetham A, Cui H . Enhanced cellular entry and efficacy of tat conjugates by rational design of the auxiliary segment. Mol Pharm. 2014; 11(3):964-73. PMC: 3993903. DOI: 10.1021/mp400619v. View

3.
Kanazawa T, Kaneko M, Niide T, Akiyama F, Kakizaki S, Ibaraki H . Enhancement of nose-to-brain delivery of hydrophilic macromolecules with stearate- or polyethylene glycol-modified arginine-rich peptide. Int J Pharm. 2017; 530(1-2):195-200. DOI: 10.1016/j.ijpharm.2017.07.077. View

4.
Liu Y, Lu Z, Mei L, Yu Q, Tai X, Wang Y . Tandem Peptide Based on Structural Modification of Poly-Arginine for Enhancing Tumor Targeting Efficiency and Therapeutic Effect. ACS Appl Mater Interfaces. 2016; 9(3):2083-2092. DOI: 10.1021/acsami.6b12611. View

5.
Nagahara H, Snyder E, Ho A, Latham D, Lissy N, Ezhevsky S . Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med. 1998; 4(12):1449-52. DOI: 10.1038/4042. View